Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04834973
Title A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors QBiotics Group Limited
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.